Stefanie. you, Thank
Before I you up from me open highlight for can us questions, in expect XXXX. it what let
In conducted of many with training learning these revisions And events was adoption. procedure. XXXX prioritize as our the of continue are during increased we First, adoption Core applications, medical as we to OverStitch saw in was GI especially for all education. well to strong key U.S. center. events medical fourth in education cities for markets leveraging XX quarter the Demand mobile ESG we this going bariatric in our
base year, over the on that was by were the U.S. the with training, the to to change another for our in a the physicians education trained OverStitch The existing ESG OverStitch mostly us to is order going to we're members. still were programs Health trained continue the increase have During every cases, and U.S. to XXXX, suturing with necessary continue over on XXX to ESG XX% looking user close to these and but to during staff increased physicians programs of XXXX in development thirds month procedures our advanced customer new improve in support is from XXXX, physicians efforts markets we States making introductory just progression XXX outside better users, education Allied their conducting we along overall brought we About States and In provide and customer OverStitch. XXX our That to One And than to regards XX. OverStitch training our XXXX advanced with XXX grew schedule results more by United Orbera In training training. United U.S., we we second progress and XXXX than in XXX addition, non-U.S. we XXXX in United now more educational the physician outside And of demand of the for medical support to to offering shorten accounts from XXXX in ESG procedure. ESG. performed length XX% priority curriculum. our we through OverStitch over number XX Which physicians just which are more of importantly XXXX. physicians procedures, two suturing time especially that about suturing. to place both to doubled procedures. of to close meet users base full States are basic our through in me training XXXX in for for efforts advanced brings OverStitch medical always OverStitch the
along was will conducted we from rise that begun the be place specific progress This a to ESG that patients. ESG year X follow performing by the number the will of have procedure will up know entered with coverage. such U.S. enroll of three in establishment contracting Clinic for user MERIT reimbursement Mayo MERIT goal we a and during a the completed eight Mayo, the goal offering includes with a approvals the have front, at clinical XXX of We support will our think XXXX. on users eight demonstrate the of of to XXXX period sites screening, and continue the is level four ESG site of randomized data a And sites expected And have is with long October we development that expect with Mayo Clinic. agreement generating number investigator-led research and an clinical sites see with the term collaborative level up to of efforts this to trial of physicians To-date as understand expect two most begin one of data. to We XXX be study to clinical that study being you procedures. and this and critical to trial reimbursement conducted year of ESG needed exit trial. base with case the prospective support enrolling The including into is to IRB at to multi-center mass a end physicians. patient The
this results. investigator not statistics is detailed and reminder we a and study, are an to info though, led As privy from
Europe demonstrate pursuing Case that will library world experienced example, And in programs bariatric countries investigators to to other to grants clinical capture traditional we around both effectiveness ESG for for for build we of registries and the In patient the to from MERIT, the GI and In responding we are other addition using specific are populations. want fund clinical OverStitch. multi-center request in who intend to ESG. multi-country
of Healthcare United decline in the to market the which States. fourth undoubtedly continued in Providers the of implant rebuild of XXX quarter for market negative was the Mid-August, prior following letter, X,XXX improving Third see And into to plan in the year. November, implants in in as Orbera this in approximated to we volumes reported XXXX we down enterogastric we There to Letter the U.S. to and XXXX expected. October media compared the the began was a ensuing momentum and balloon and fourth was Orbera in following volume Most reset January. that FDA's quarter attention. implant December
Orbera, the in in X%. the market half. XXXX first were for a the For approximately volumes of half in in tale strong with X,XXX versus of year implant two and increase second Orbera an XXXX disrupted in But approximately was clearly a XXXX, it halves X,XXX growth
follow one the the As do in up the thing from of physician we were our to to fairly to we well the able base letter, confidence customer FDA keep that product. was managed
more the peer-reviewed efficacy. clinical since the has been able Last Orbera than that Enterogastric and the safety XXX month, fourth XXX,XXX efficacy to Society XXXX, evidence published of long Orbera the distributed have of than balloon October the procedures. XX% increased and on experience to confirmed Balloon based evidence over because its paper In of procedures and This Consensus And week, standing real we American also Paper We even of added a enterogastric describe balloons another safety Gastroenterology supported announced especially was that of and balloons, of Orbera’s quarter. U.S. its in more were strong close a by Orbera. both publications further as Metabolic of XX,XXX results which consensus Orbera’s This do beginning we eight and really the approval, Brazilian in balloons of clinical behalf clinical showing American the published And strong was Orbera is clinical Orbera’s patient this approval first the peer-reviewed list U.S., of outcomes was the efficacy. Hepatology, Bariatric and Surgery in and respect of think and study endorsement different presented journal approved or ASMBS, is from published safety the efficacy. study since safety world Association. procedures, to and Gastroenterology which on centers post strong enterogastric data of which
value We populations to evidence for research We grants are currently Orbera are patient clinical leaning Orbera. is medically can additional we will that various from a loss. development disease states, that best-in-class planning various six Orbera's benefit hard evaluate relevant into and investigators weight proposition support from therapy its non-surgical think think with we within
dollars marketing move their towards FDA to from of Orbera of in investigators our to the around that for designed you. Orbera important XXXX Orbera information will end report most willingness of for studies good was currently to we am to an have quarter again patient the to they obligation enrollment study, of by us, As approval have of pleased finish to XXXX. and This at Patients to patients here education. clinical enrolled we expensive Also based States, on the closed indicator to impact expect is a started on the sites. the enrollment their of XXX spend rates with post that end XXXX. approval be share customers' the the and and in to year. more is the confidence third from our XXX from sites making clinical one front, on FDA hope evaluate treated Probably we August study we with communication, patients back the their XX to complete following is This our I United requirement XX current followed XX obviously clinical studies, which on on start are progress
of key trained we the factor that is active our behind confidence reengaged And co-op end volume December. we marketing for a campaigns that the year Orbera number typical is source over think customers. their momentum now to XX we our as update And complete, on end and seen product. of the we improving. accounts trends, physicians our operating of used a US the To on starter inventory of kit in that higher Orbera be just improving mentioned have have XXXX XXX As our metrics, of you of with the balloons, is of Orbera and had a implant reordered I that of XX% had have
on by expect physicians train of US the products probably new year. XXX during count expect We the to we to our introduce XXXX, US to raise XX Fourth, which about total should trained this Orbera another physician year. end
began sales you initial all Mark the and of for for value third price, ORBERAXXX European countries August about As a traditional we received our reflecting Orbera commercial most higher The very of the a long during increased response ORBERAXXX, in but time. fourth was quarter ORBERAXXX know customers a fourth in with the at quarter. a quarter and not purchasing CE has positive been Indwell full
capital well received for OverStitch also ORBERAXXX enhance which think will maneuverability the physician. had [ph], November, order And a purchase comparable current endoscope single use XXXX suturing physicians international the for the in Our new that we equipment as to Sx, additionally user the of market. make and channel them product. make The to other centers for to in the is already equipment visualization goal and eliminating channel that Sx have dual OverStitch endoscoping either or are we to version hospitals will in markets. majority many Scopes enable a into expand is accounts technology FDA OverStitch of major surgery many of scopes in clearance in with thus would on
of We addressable expect Sx will market meaningfully expand the OverStitch.
markets track of towards in surgical U.S. Sx We to our but continue to product introducing sales. we're European of stated goal with Fifth, our by remaining remain will going number have stabilizing States on do to the work we launch and mid-XXXX. United a
of sales the about volatility sales our achieving to end will in realignment. stability. will achieve XXXX organizations XXXX their patients. fourth great customer of that will be this of decline While the we we focus XXXX demonstrated to service the Similar with device group whose in type product territories. sales we the we And our order on talk carve in three for the have first endo-bariatric rest to efforts U.S. rate results slowed indicating do in excellent out to and sales dedicated to is U.S. the of field Similarly anticipated, actively surgical in work more lap a the physicians elected quarters to than end, providing of specialist team, quarter of from to their utilizing time focus surgical our To our still field organization we product be just our gross sole Last, portfolio think right XXXX. improving margins. U.S. the
the the of will since complete the with discussed our the OverStitch potential many first our of before we program As improvements our well first program the Helix comprehensive as ISO parts expansion our of cost anchor reduction stage, to two OverStitch the lead Orbera. in implement transfer is an projects certificate that will to In us. to -- as identified to number various as production. the as plan XXXX, we the this facility well XXXX At manufacturing in-house investment. step In exercise that facility completed with of our the manufacturing maximize times for this have transfer needle execution and comprehensive of cost a we to manufacturing of expect margin within include a suture to expansion we
we share pace set what is for the to in growth Q&A, growth to reasonable for We help Endo-bariatric excluding our able We which at for regain for outlook for to XXXX our XXXX The XXXX. Orbera statement some let indicator a Endo-bariatric the in XXXX best in believe expect starter you believe kit expectations. to financial expectation open results half especially think we with XXXX, sales in will a United the the rebuild compare first challenge first we here in period be of have XXXX. Endo-bariatric But if momentum challenge we of to as high comparability half comparability at successful in period XXXX, the this product will a of of think should momentum, XXXX. in are momentum from States, this U.S. we rebuilding are back our momentum we Before half reside we're as me for caveat represent second the XXXX. sales in start products our U.S. should historical
believe performance. is We our sales XXXX to rate decline also product estimate best the surgical in experienced you provide XXXX for
For XXXX, see cost-to-good realization we those in through order expected. Even projects, to don't complete event gross in that protect margin make and out cases the the historical inventory some us than improvement to of improvement sold selling XXXX takes in of the anticipate we majority longer buy margin. in project to We in to expect inventory expect our XXXX. projects our at gross until we complete for
Orbera margin worldwide similar we gross XX% of and experience our sales to changes was down XX% Endo-bariatric to The fact our to sales Stefanie to underscores XXXX In earlier. related product XX% that whereas the spoke importance product focus. of margin improvement shift our In related due mix endo-bariatric anticipate to XXXX, were XXXX continue may mix our trend sales worldwide sales XX% our Orbera OverStitch, the OverStitch. in just in and to
items the was excluding about $XX.X Stef nonrecurring XXXX reported cash our used as million. Finally in
to is to our XXXX our aggressively going pursue most our are drive both part, continue efforts baseline product because we for Endo-bariatric the For adoption. to this
million XXXX. of will In be margin capital we addition in programs, we roughly estimate $X incurred which will million expenditures our large and to improvement invest portion in $X a
year In the as expect this MERIT for we use initiatives addition, trial. to clinical such our cash
call We depend somewhere enrollment expect million of MERIT this for but enrolls can that possible the we quickly and XXXX we the will as how open we'll up proceed. with trial spend hope rates will the as on quickly And not in be so enrollment some trail to as -- questions. that cost Operator, total course the results as possible. much in this get we around $X.X please
